Abstract
Purpose To evaluate anterior segment optical coherence tomography (AS-OCT) parameters of bleb wall thickness (BWT) and total bleb height (TBH) in the early postoperative phase after Preserflo Microshunt (PM) implantation for their correlation to (a) surgical revision and (b) AS-OCT angiography (AS-OCTA) derived bleb vessel density (BVD).
Methods A total of 23 patients with pharmacologically uncontrolled open angle glaucoma were studied. Post-operatively (at 1, 2, and 4 weeks and 2, 3, 6, 9, and 12 months) AS-OCT measurements of BWT/TBH and AS-OCTA measurements of BVD were acquired. Surgical revisions (needling or open revision) were recorded. Correlations of BWT and TBH to (a) need for surgical revision and to (b) BVD were assessed.
Results In 10 of 23 patients, surgical revisions were performed 4 to 48 weeks after PM implantation. At 1, 2, and 4 weeks after surgery neither BWT nor TBH were significantly associated with future surgical revisions (BWT/TBH p-values: 1W 0.217/0.878, 2W 0.670/0.528, 4W 0.171/0.430). No correlations between BWT or TBH and BVD were found for any evaluated timepoint (1W, 2W, 4W).
Conclusions Structural AS-OCT parameters were not predictive of the need for surgical revision after PM implantation. Consistent with this finding, these parameters were also not correlated with AS-OCTA derived BVD, which was shown to be a good biomarker for failure in a previous analysis. The discrepancy to similar studies after trabeculectomy may be due to bleb drainage differences between TE and PM. BVD seems to be a better predictor of surgical revision after PM implantation than BWT/TBH.
Competing Interest Statement
CAS: Santen(Consultant, Research Support), Zeiss(Honorarium), AbbVie(Consultant, Honorarium), Elios Vision (Consultant, Honorarium). ASH: Allergan(C), Amydis(C), Celanese(C), Diagnosys(F), Equinox(C), Glaukos(C,F), Heidelberg Engineering(F), QLARIS(C), Santen(C), Topcon(C).
Funding Statement
This study was funded by NIH grant R01EY030501 (ASH) and an unrestricted grant from Santen SA. Santen SA was not involved in study design and conduct, data analysis and interpretation or manuscript production.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
name: Ethics Committee of the Johannes Kepler University Linz decision: approval (EC-No.: B-142-17)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
